Ajanta Pharma Limited

BSE: 532331 NSE: AJANTPHARM
Ajanta Pharma Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials and compliance.
CIN L24230MH1979PLC022059 Incorporated 31 December 1979 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: AJANTPHARM · BSE: 532331 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹5,452.86 Cr
▲ 17.31% YoY
EBITDA · FY 2026
₹1,566.9 Cr
▲ 15.72% YoY
Net profit · FY 2026
₹1,056 Cr
▲ 14.73% YoY
Authorised capital
₹30 Cr
Registered with MCA
Paid-up capital
₹24.99 Cr
Issued & subscribed
Open charges
₹65 Cr
Satisfied ₹548.84 Cr
Company age
47 yrs
Est. 1979
Employees · EPFO
7,869
Latest available

About Ajanta Pharma Limited

Data last updated: 28 January 2026

Ajanta Pharma Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 31 December 1979, the company has been in operation for over 47 years.

Registered with ROC Mumbai under CIN L24230MH1979PLC022059. Listed on BSE: 532331 and NSE: AJANTPHARM.

Capital: an authorised share capital of ₹30 Cr and a paid-up capital of ₹24.99 Cr. Formerly known as Ajanta Pharma Private Limited. It is led by directors including David Paul Rasquinha and Simi Manohar Lal Thapar.

Last AGM: 17 July 2025. Financial statements filed for year ended 31 March 2025. Office: Mumbai, Maharashtra.

As per the financials filed for FY 2025, the company reported a revenue of ₹4,742.6 Cr, a growth of 10% compared to the previous year.

The company has a workforce of approximately 7,869 employees as per the latest available data.

The company is associated with 2 brands - Resinno, Ajanta Pharma. As per MCA filings, the company has open charges of ₹65 Cr and satisfied charges of ₹548.84 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website ajantapharma.com.

Company Details of Ajanta Pharma Limited
CIN L24230MH1979PLC022059
Registration Number 022059
Incorporation Date 31 December 1979
ROC Mumbai
Listing Status Listed (BSE: 532331, NSE: AJANTPHARM)
Company Status Active
Date of Last AGM 17 July 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Yogesh Mannalal Agrawal Managing Director Madhusudan Bhagwandas Agrawal Whole-Time Director Rajesh Mannalal Agrawal Whole-Time Director
Contact Details
  • Email
    *****@*****.com
  • Telephone
    +91-****-******
  • Website
    ajantapharma.com
  • Social Media
  • Registered Address
    Ajanta Tower 54 – A M Vasanji Road, Chakala Andheri (E), Mumbai, Maharashtra, India – 400093
  • Industry
    Pharma, Drug Formulation & Development
Company report
Ajanta Pharma Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Ajanta Pharma Limited report

Financials, compliance, directors, charges, ownership and filings for Ajanta Pharma Limited in one report.

10-year financials Directors & ownership Charges & compliance

Associated Brands with Ajanta Pharma Limited

Ajanta Pharma Limited operates two associated brands: Resinno and Ajanta Pharma. These brands represent Ajanta Pharma Limited's diversified market presence and brand portfolio.

Brand Description Website
Resinno
Serves as a CDMO specializing in the manufacturing of active pharmaceutical ingredients. resinnobiotech.com
Ajanta Pharma
Generic pharmaceutical products are manufactured across multiple therapeutic segments. ajantapharma.com

Competitors & Alternatives of Ajanta Pharma Limited

Brands and companies operating in the same space as Ajanta Pharma Limited include Laurus Labs, Symbiotec, Beijing Biostar Technologies and 6 more.

Competitor Description Location Founded
Laurus Labs Laurus Labs Pharmaceutical and biotechnology company Hyderabad, India, India 2005
Symbiotec Symbiotec Non-sterile steroid hormone-based APIs and intermediates are manufactured. Indore, India, India 2002
Beijing Biostar Technologies Beijing Biostar Technologies APIs, intermediates, and biochemical reagents are developed and manufactured. Beijing, China, China 2002
Sterling Pharma Solutions Sterling Pharma Solutions Contract development, manufacturing, and analytical services for APIs are offered. Dudley, United Kingdom, United Kingdom 2016
Provepharm Life Solutions Provepharm Life Solutions APIs and drug products are developed and valorized in pharmaceuticals. Marseille, France, France 1998
Hikal Hikal APIs and intermediates are produced via custom synthesis and research. Mumbai, India, India 1988
Snapdragon Chemistry Snapdragon Chemistry Drug discovery and development service provider Cambridge, United States, United States 2014
SeQuent SeQuent APIs are developed and manufactured for therapeutic areas. Bengaluru, India, India 2002
Jubilant Pharma Jubilant Pharma Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company. Noida, India, India 1978

Business Activity of Ajanta Pharma Limited

Ajanta Pharma Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products *********

Auditor Details of Ajanta Pharma Limited

Ajanta Pharma Limited is audited by B S R & Co. LLP (ICAI peer reviewed, certificate valid till 2025-07-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
B S R & Co. LLP (ICAI peer reviewed, certificate valid till 2025-07-31) FY 2026 Declaration of unmodified opinion

Board of Directors of Ajanta Pharma Limited

Ajanta Pharma Limited is currently managed by 10 directors, with 30 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
David Paul Rasquinha
Also directs: Ion Exchange (India) Limited, Unity Small Finance Bank Limited, Hsbc Trustees (India) Private Limited and 2 more
Director 02 May 2024 2 Years 2 Months Current
Simi Manohar Lal Thapar
Also directs: Csi Renting India Private Limited
Director 02 May 2024 2 Years 2 Months Current
Rajesh Shashikant Dalal
Also directs: Surya Women And Children Llp, Laxmi Dental Limited, Entero Healthcare Solutions Limited and 1 more
Director 02 May 2024 2 Years 2 Months Current
Madhusudan Bhagwandas Agrawal
Also directs: Inspira Realty Llp, Ir Jpv Realty Llp, Inspira Estate Llp and 5 more
Whole-Time Director 31 Dec 1979 46 Years 6 Months Current
Medha Vinay Joshi Director 02 May 2024 2 Years 2 Months Current
Mannalal Bhagwandas Agrawal Director 31 Dec 1979 46 Years 6 Months Current
Showing 6 of 10 current directors. View all directors

Financials of Ajanta Pharma Limited FY 2026 filings available

Ajanta Pharma Limited reported revenue of ₹5,452.86 Cr (up 17.31% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.

Revenue · FY 2026
₹5,452.86 Cr ▲ 17.31%
Profit · FY 2026
₹1,056 Cr ▲ 14.73%
EBITDA · FY 2026
₹1,566.9 Cr ▲ 15.72%
Revenue₹ Cr · Consolidated02,0004,0006,000FY 2020: ₹2,588 Cr2,588FY 2020FY 2021: ₹2,890 Cr · +11.7% YoY2,890+11.7%FY 2021FY 2022: ₹3,341 Cr · +15.6% YoY3,341+15.6%FY 2022FY 2023: ₹3,743 Cr · +12% YoY3,743+12%FY 2023FY 2024: ₹4,209 Cr · +12.5% YoY4,209+12.5%FY 2024FY 2025: ₹4,648 Cr · +10.4% YoY4,648+10.4%FY 2025FY 2026: ₹5,453 Cr · +17.3% YoY5,453+17.3%FY 2026
Net Profit₹ Cr · Consolidated05001,0001,500FY 2020: ₹468 Cr468FY 2020FY 2021: ₹654 Cr · +39.8% YoY654+39.8%FY 2021FY 2022: ₹713 Cr · +9% YoY713+9%FY 2022FY 2023: ₹588 Cr · -17.5% YoY588-17.5%FY 2023FY 2024: ₹816 Cr · +38.8% YoY816+38.8%FY 2024FY 2025: ₹920 Cr · +12.8% YoY920+12.8%FY 2025FY 2026: ₹1,056 Cr · +14.7% YoY1,056+14.7%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year05001,0001,500Q1'25: ₹1,145 Cr · +12.1% YoY1,145+12.1%Q1'25Q2'25: ₹1,187 Cr · +15.4% YoY1,187+15.4%Q2'25Q3'25: ₹1,146 Cr · +3.7% YoY1,146+3.7%Q3'25Q4'25: ₹1,170 Cr · +11% YoY1,170+11%Q4'25Q1'26: ₹1,303 Cr · +13.8% YoY1,303+13.8%Q1'26Q2'26: ₹1,354 Cr · +14.1% YoY1,354+14.1%Q2'26Q3'26: ₹1,375 Cr · +20% YoY1,375+20%Q3'26Q4'26: ₹1,422 Cr · +21.5% YoY1,422+21.5%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹5,452.86 Cr ₹4,648.1 Cr ₹4,208.71 Cr ₹3,742.64 Cr ₹3,340.99 Cr ₹2,889.69 Cr ₹2,587.87 Cr
Other Income ₹172.07 Cr ₹94.5 Cr ₹84.6 Cr ₹98.64 Cr ₹115.68 Cr ₹25.98 Cr ₹92.19 Cr
Total Income ₹5,624.93 Cr ₹4,742.6 Cr ₹4,293.31 Cr ₹3,841.28 Cr ₹3,456.67 Cr ₹2,915.67 Cr ₹2,680.06 Cr
Cost of Materials Consumed ₹916.51 Cr ₹846.6 Cr ₹939.43 Cr ₹878.36 Cr ₹779.34 Cr ₹706.41 Cr ₹560.33 Cr
Purchases of Stock-in-Trade ₹229.79 Cr ₹249.8 Cr ₹166.35 Cr ₹146.28 Cr ₹136.1 Cr ₹89.54 Cr ₹112.13 Cr
Changes in Inventories ₹37.46 Cr -₹25.64 Cr -₹39.21 Cr ₹25.76 Cr -₹83.17 Cr -₹150.9 Cr -₹16.75 Cr
Employee Benefit Expense ₹1,291.15 Cr ₹1,089.69 Cr ₹900.34 Cr ₹785.14 Cr ₹645.78 Cr ₹548.25 Cr ₹485.59 Cr
Finance Costs ₹16.11 Cr ₹20.73 Cr ₹7.21 Cr ₹5.84 Cr ₹10.2 Cr ₹8.27 Cr ₹11.91 Cr
Depreciation & Amortisation ₹173.14 Cr ₹144.11 Cr ₹135.4 Cr ₹130.8 Cr ₹125.3 Cr ₹116.09 Cr ₹95.72 Cr
Other Expenses ₹1,583.12 Cr ₹1,228.15 Cr ₹1,069.86 Cr ₹1,123.85 Cr ₹933.64 Cr ₹697.83 Cr ₹763.24 Cr
Total Expenses ₹4,247.28 Cr ₹3,553.44 Cr ₹3,179.38 Cr ₹3,096.03 Cr ₹2,547.19 Cr ₹2,015.49 Cr ₹2,012.17 Cr
Profit Before Exceptional Items & Tax ₹1,377.65 Cr ₹1,189.16 Cr ₹1,113.93 Cr ₹745.25 Cr ₹909.48 Cr ₹900.18 Cr ₹667.89 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 -₹3.92 Cr
Profit Before Tax ₹1,377.65 Cr ₹1,189.16 Cr ₹1,113.93 Cr ₹745.25 Cr ₹909.48 Cr ₹900.18 Cr ₹663.97 Cr
Total Tax Expense ₹321.65 Cr ₹268.77 Cr ₹297.76 Cr ₹157.27 Cr ₹196.8 Cr ₹246.31 Cr ₹196.27 Cr
Net Profit ₹1,056 Cr ₹920.39 Cr ₹816.17 Cr ₹587.98 Cr ₹712.68 Cr ₹653.87 Cr ₹467.7 Cr
  attributable to Owners ₹1,056 Cr ₹920.39 Cr ₹816.98 Cr ₹0 ₹0 - -
  attributable to NCI ₹0 ₹0 ₹0 ₹0 ₹0 - -
Other Comprehensive Income ₹29.08 Cr ₹1.85 Cr ₹81 Lakh ₹14.85 Cr -₹7.97 Cr -₹6.45 Cr ₹5.56 Cr
Total Comprehensive Income ₹1,085.08 Cr ₹922.24 Cr ₹816.98 Cr ₹602.83 Cr ₹704.71 Cr ₹647.42 Cr ₹473.26 Cr
EBITDA (computed) ₹1,566.9 Cr ₹1,354 Cr ₹1,256.54 Cr ₹881.89 Cr ₹1,044.98 Cr ₹1,024.54 Cr ₹775.52 Cr
Basic EPS ₹84.53 ₹73.56 ₹64.82 ₹45.89 ₹82.45 ₹75.09 ₹53.60
Diluted EPS ₹84.51 ₹73.53 ₹64.77 ₹45.89 ₹82.45 ₹75.09 ₹53.60
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹6,154.84 Cr ₹5,014.95 Cr ₹4,638.39 Cr ₹4,679.02 Cr
Non-current Assets ₹2,419.41 Cr ₹2,171.92 Cr ₹1,907.47 Cr ₹1,845.02 Cr
Current Assets ₹3,735.43 Cr ₹2,829.7 Cr ₹2,722.07 Cr ₹2,825.18 Cr
Property, Plant & Equipment ₹1,726.35 Cr ₹1,624.87 Cr ₹1,384.13 Cr ₹1,407.83 Cr
Inventories ₹938.54 Cr ₹903.85 Cr ₹828.36 Cr ₹815.63 Cr
Trade Receivables ₹1,853.88 Cr ₹1,182.74 Cr ₹1,246.84 Cr ₹1,056.9 Cr
Cash & Equivalents ₹103.26 Cr ₹175.12 Cr ₹129.49 Cr ₹329.83 Cr
Equity (Net Worth) ₹4,527.09 Cr ₹3,790.29 Cr ₹3,567.36 Cr ₹3,387.99 Cr
Equity Share Capital ₹25.07 Cr ₹25.07 Cr ₹25.27 Cr ₹25.27 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹1.25 Cr
Borrowings (Current) ₹211.99 Cr ₹2.59 Cr ₹1.49 Cr ₹18 Lakh
Total Debt (computed) ₹211.99 Cr ₹2.59 Cr ₹1.49 Cr ₹1.43 Cr
Current Liabilities ₹1,415.75 Cr ₹996.1 Cr ₹895.25 Cr ₹1,139.28 Cr
Total Liabilities ₹1,627.75 Cr ₹1,224.66 Cr ₹1,071.03 Cr ₹1,291.03 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹529.19 Cr ₹1,157.23 Cr ₹785.07 Cr ₹791.78 Cr ₹562.04 Cr
Investing Cash Flow -₹428.92 Cr -₹376.52 Cr ₹65.39 Cr -₹559.6 Cr -₹74.1 Cr
Financing Cash Flow -₹167.92 Cr -₹733.41 Cr -₹1,051.06 Cr -₹107.87 Cr -₹460.04 Cr
Capital Expenditure ₹365.16 Cr ₹317.92 Cr ₹152.41 Cr ₹174.49 Cr ₹148.84 Cr
Free Cash Flow (computed) ₹164.03 Cr ₹839.31 Cr ₹632.66 Cr ₹617.29 Cr ₹413.2 Cr
Dividends Paid ₹349.72 Cr ₹349.37 Cr ₹642.17 Cr ₹89.69 Cr ₹82.21 Cr
Net Change in Cash -₹71.86 Cr ₹45.63 Cr -₹200.34 Cr ₹123.47 Cr ₹28.85 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹1,421.64 Cr ₹1,374.84 Cr ₹1,353.73 Cr ₹1,302.65 Cr ₹1,170.41 Cr ₹1,146.13 Cr ₹1,186.64 Cr ₹1,144.92 Cr ₹1,054.08 Cr ₹1,105.15 Cr ₹1,028.44 Cr ₹1,021.04 Cr
Other Income ₹61.43 Cr ₹24.97 Cr ₹59.34 Cr ₹26.33 Cr ₹18.11 Cr ₹30.44 Cr ₹19.48 Cr ₹26.47 Cr ₹35.5 Cr ₹13.59 Cr ₹21.33 Cr ₹31.75 Cr
Total Income ₹1,483.07 Cr ₹1,399.81 Cr ₹1,413.07 Cr ₹1,328.98 Cr ₹1,188.52 Cr ₹1,176.57 Cr ₹1,206.12 Cr ₹1,171.39 Cr ₹1,089.58 Cr ₹1,118.74 Cr ₹1,049.77 Cr ₹1,052.79 Cr
Cost of Materials Consumed ₹256.76 Cr ₹235.07 Cr ₹217.6 Cr ₹207.08 Cr ₹190.96 Cr ₹210.14 Cr ₹207.09 Cr ₹238.41 Cr ₹259.03 Cr ₹239.05 Cr ₹223.54 Cr ₹217.81 Cr
Purchases of Stock-in-Trade ₹71.35 Cr ₹53.55 Cr ₹53.26 Cr ₹51.63 Cr ₹80.18 Cr ₹78.55 Cr ₹45.79 Cr ₹45.28 Cr ₹40.44 Cr ₹39.29 Cr ₹46.98 Cr ₹39.64 Cr
Changes in Inventories -₹23.3 Cr -₹2.36 Cr ₹45.95 Cr ₹17.17 Cr ₹12.28 Cr -₹30.88 Cr ₹8.8 Cr -₹15.84 Cr -₹35.09 Cr ₹15.83 Cr -₹14.4 Cr -₹5.55 Cr
Employee Benefit Expense ₹340.72 Cr ₹330.52 Cr ₹317.01 Cr ₹302.9 Cr ₹279.78 Cr ₹265.17 Cr ₹260.96 Cr ₹283.78 Cr ₹233.51 Cr ₹231.35 Cr ₹222.27 Cr ₹213.21 Cr
Finance Costs ₹2.36 Cr ₹5.1 Cr ₹3.39 Cr ₹5.26 Cr ₹6.07 Cr ₹7.91 Cr ₹6.02 Cr ₹73 Lakh ₹1.53 Cr ₹2.49 Cr ₹2.34 Cr ₹85 Lakh
Depreciation & Amortisation ₹45.37 Cr ₹43.51 Cr ₹42.97 Cr ₹41.29 Cr ₹39.78 Cr ₹35.97 Cr ₹34.39 Cr ₹33.97 Cr ₹34.25 Cr ₹34.26 Cr ₹33.71 Cr ₹33.18 Cr
Other Expenses ₹442.7 Cr ₹375.82 Cr ₹392.08 Cr ₹372.52 Cr ₹310.06 Cr ₹302.32 Cr ₹352.83 Cr ₹262.94 Cr ₹277.87 Cr ₹265.56 Cr ₹259.39 Cr ₹284.61 Cr
Total Expenses ₹1,135.96 Cr ₹1,041.21 Cr ₹1,072.26 Cr ₹997.85 Cr ₹919.11 Cr ₹869.18 Cr ₹915.88 Cr ₹849.27 Cr ₹811.54 Cr ₹827.83 Cr ₹773.83 Cr ₹783.75 Cr
Profit Before Exceptional Items & Tax ₹347.11 Cr ₹358.6 Cr ₹340.81 Cr ₹331.13 Cr ₹269.41 Cr ₹307.39 Cr ₹290.24 Cr ₹322.12 Cr ₹278.04 Cr ₹290.91 Cr ₹275.94 Cr ₹269.04 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹347.11 Cr ₹358.6 Cr ₹340.81 Cr ₹331.13 Cr ₹269.41 Cr ₹307.39 Cr ₹290.24 Cr ₹322.12 Cr ₹278.04 Cr ₹290.91 Cr ₹275.94 Cr ₹269.04 Cr
Total Tax Expense ₹80.41 Cr ₹84.83 Cr ₹80.62 Cr ₹75.79 Cr ₹44.15 Cr ₹74.51 Cr ₹73.76 Cr ₹76.35 Cr ₹75.32 Cr ₹80.88 Cr ₹80.64 Cr ₹60.92 Cr
Net Profit ₹266.7 Cr ₹273.77 Cr ₹260.19 Cr ₹255.34 Cr ₹225.26 Cr ₹232.88 Cr ₹216.48 Cr ₹245.77 Cr ₹202.72 Cr ₹210.03 Cr ₹195.3 Cr ₹208.12 Cr
  attributable to Owners ₹266.7 Cr ₹273.77 Cr ₹260.19 Cr ₹255.34 Cr ₹225.26 Cr ₹232.88 Cr ₹216.48 Cr ₹238.43 Cr ₹196.33 Cr ₹0 ₹0 ₹0
  attributable to NCI ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Other Comprehensive Income ₹18.11 Cr ₹2.51 Cr ₹8.3 Cr ₹16 Lakh ₹2.04 Cr ₹1.44 Cr ₹5.71 Cr -₹7.34 Cr -₹6.39 Cr ₹2.76 Cr ₹7.08 Cr -₹2.64 Cr
Total Comprehensive Income ₹284.81 Cr ₹276.28 Cr ₹268.49 Cr ₹255.5 Cr ₹227.3 Cr ₹234.32 Cr ₹222.19 Cr ₹238.43 Cr ₹196.33 Cr ₹212.79 Cr ₹202.38 Cr ₹205.48 Cr
EBITDA (computed) ₹394.84 Cr ₹407.21 Cr ₹387.17 Cr ₹377.68 Cr ₹315.26 Cr ₹351.27 Cr ₹330.65 Cr ₹356.82 Cr ₹313.82 Cr ₹327.66 Cr ₹311.99 Cr ₹303.07 Cr
Basic EPS ₹21.35 ₹21.91 ₹20.83 ₹20.44 ₹18.00 ₹18.60 ₹17.27 ₹19.54 ₹16.10 ₹16.68 ₹15.51 ₹16.53
Diluted EPS ₹21.34 ₹21.91 ₹20.82 ₹20.43 ₹18.00 ₹18.59 ₹17.26 ₹19.53 ₹16.09 ₹16.67 ₹15.50 ₹16.53
Latest 12 quarters shown of 25 on record.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹4,845.92 Cr ₹4,322.04 Cr ₹3,971.12 Cr ₹3,411.27 Cr ₹3,140.64 Cr ₹2,718.59 Cr ₹2,196.42 Cr
Other Income ₹204.4 Cr ₹119.87 Cr ₹116.48 Cr ₹132.75 Cr ₹139.73 Cr ₹103.57 Cr ₹184.2 Cr
Total Income ₹5,050.32 Cr ₹4,441.91 Cr ₹4,087.6 Cr ₹3,544.02 Cr ₹3,280.37 Cr ₹2,822.16 Cr ₹2,380.62 Cr
Cost of Materials Consumed ₹916.52 Cr ₹846.6 Cr ₹939.43 Cr ₹878.36 Cr ₹773.04 Cr ₹704.09 Cr ₹556.22 Cr
Purchases of Stock-in-Trade ₹218.06 Cr ₹184 Cr ₹162.16 Cr ₹149.04 Cr ₹116.12 Cr ₹100.59 Cr ₹98.73 Cr
Changes in Inventories -₹57.32 Cr -₹18.58 Cr -₹22.17 Cr -₹21.99 Cr -₹56.6 Cr -₹74.6 Cr ₹9.02 Cr
Employee Benefit Expense ₹1,194.05 Cr ₹1,010.9 Cr ₹834.16 Cr ₹720.41 Cr ₹585.87 Cr ₹498.11 Cr ₹437.82 Cr
Finance Costs ₹2.59 Cr ₹4.6 Cr ₹6.8 Cr ₹5.23 Cr ₹9.12 Cr ₹6.9 Cr ₹9.1 Cr
Depreciation & Amortisation ₹168.77 Cr ₹139.93 Cr ₹132.16 Cr ₹126.95 Cr ₹120.96 Cr ₹111.49 Cr ₹91.29 Cr
Other Expenses ₹1,376.62 Cr ₹1,094.4 Cr ₹938.11 Cr ₹986.17 Cr ₹831.32 Cr ₹573.49 Cr ₹561.85 Cr
Total Expenses ₹3,819.29 Cr ₹3,261.85 Cr ₹2,990.65 Cr ₹2,844.17 Cr ₹2,379.83 Cr ₹1,920.07 Cr ₹1,764.03 Cr
Profit Before Exceptional Items & Tax ₹1,231.03 Cr ₹1,180.06 Cr ₹1,096.95 Cr ₹699.85 Cr ₹900.54 Cr ₹902.09 Cr ₹616.59 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 -₹3.92 Cr
Profit Before Tax ₹1,231.03 Cr ₹1,180.06 Cr ₹1,096.95 Cr ₹699.85 Cr ₹900.54 Cr ₹902.09 Cr ₹612.67 Cr
Total Tax Expense ₹284.21 Cr ₹263.17 Cr ₹289.71 Cr ₹141.13 Cr ₹180.68 Cr ₹226.45 Cr ₹171.54 Cr
Net Profit ₹946.82 Cr ₹916.89 Cr ₹807.24 Cr ₹558.72 Cr ₹719.86 Cr ₹675.64 Cr ₹441.13 Cr
Other Comprehensive Income -₹31 Lakh -₹5.83 Cr -₹2.52 Cr -₹2.27 Cr ₹36 Lakh -₹1.33 Cr -₹2.55 Cr
Total Comprehensive Income ₹946.51 Cr ₹911.06 Cr ₹804.72 Cr ₹556.45 Cr ₹720.22 Cr ₹674.31 Cr ₹438.58 Cr
EBITDA (computed) ₹1,402.39 Cr ₹1,324.59 Cr ₹1,235.91 Cr ₹832.03 Cr ₹1,030.62 Cr ₹1,020.48 Cr ₹716.98 Cr
Basic EPS ₹75.79 ₹73.28 ₹64.11 ₹43.61 ₹83.28 ₹77.59 ₹50.55
Diluted EPS ₹75.77 ₹73.25 ₹64.06 ₹43.61 ₹83.28 ₹77.59 ₹50.55
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹5,316.72 Cr ₹4,554.25 Cr ₹4,217.44 Cr ₹4,304.79 Cr
Non-current Assets ₹2,198.06 Cr ₹1,978.19 Cr ₹1,775.77 Cr ₹1,752.77 Cr
Current Assets ₹3,118.66 Cr ₹2,567.21 Cr ₹2,432.82 Cr ₹2,544.1 Cr
Property, Plant & Equipment ₹1,722.63 Cr ₹1,621.61 Cr ₹1,376.86 Cr ₹1,399.84 Cr
Inventories ₹844.71 Cr ₹739.29 Cr ₹677.79 Cr ₹683.77 Cr
Trade Receivables ₹1,365.77 Cr ₹1,225.81 Cr ₹1,207.67 Cr ₹977.63 Cr
Cash & Equivalents ₹89.04 Cr ₹48.6 Cr ₹61.78 Cr ₹268.85 Cr
Equity (Net Worth) ₹4,223.53 Cr ₹3,625.31 Cr ₹3,413.57 Cr ₹3,246.45 Cr
Equity Share Capital ₹25.07 Cr ₹25.07 Cr ₹25.27 Cr ₹25.27 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹0
Borrowings (Current) ₹0 ₹0 ₹0 ₹0
Total Debt (computed) ₹0 ₹0 ₹0 ₹0
Current Liabilities ₹891.03 Cr ₹710.72 Cr ₹629.19 Cr ₹907.84 Cr
Total Liabilities ₹1,093.19 Cr ₹928.94 Cr ₹803.87 Cr ₹1,058.34 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹803.83 Cr ₹1,053.8 Cr ₹735.35 Cr ₹736.29 Cr ₹542.36 Cr
Investing Cash Flow -₹399.55 Cr -₹349.6 Cr ₹105.02 Cr -₹501.31 Cr -₹66.04 Cr
Financing Cash Flow -₹359.62 Cr -₹715.71 Cr -₹1,047.7 Cr -₹105.12 Cr -₹457.32 Cr
Capital Expenditure ₹367.28 Cr ₹317.2 Cr ₹152.57 Cr ₹175.66 Cr ₹146.53 Cr
Free Cash Flow (computed) ₹436.55 Cr ₹736.6 Cr ₹582.78 Cr ₹560.63 Cr ₹395.83 Cr
Dividends Paid ₹349.72 Cr ₹349.37 Cr ₹642.17 Cr ₹89.69 Cr ₹82.21 Cr
Net Change in Cash ₹40.45 Cr -₹13.18 Cr -₹207.07 Cr ₹129.02 Cr ₹19.95 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹1,210.53 Cr ₹1,206.59 Cr ₹1,220.24 Cr ₹1,208.56 Cr ₹1,013.94 Cr ₹1,101.92 Cr ₹1,128.91 Cr ₹1,077.27 Cr ₹926.07 Cr ₹1,085.29 Cr ₹945.18 Cr ₹1,014.58 Cr
Other Income ₹62.98 Cr ₹25.76 Cr ₹75.03 Cr ₹40.63 Cr ₹17.93 Cr ₹33.23 Cr ₹40.34 Cr ₹28.37 Cr ₹33.68 Cr ₹13.73 Cr ₹52.16 Cr ₹31.46 Cr
Total Income ₹1,273.51 Cr ₹1,232.35 Cr ₹1,295.27 Cr ₹1,249.19 Cr ₹1,031.87 Cr ₹1,135.15 Cr ₹1,169.25 Cr ₹1,105.64 Cr ₹959.75 Cr ₹1,099.02 Cr ₹997.34 Cr ₹1,046.04 Cr
Cost of Materials Consumed ₹256.77 Cr ₹235.07 Cr ₹217.6 Cr ₹207.08 Cr ₹190.96 Cr ₹210.14 Cr ₹207.09 Cr ₹238.41 Cr ₹259.03 Cr ₹239.04 Cr ₹223.55 Cr ₹217.81 Cr
Purchases of Stock-in-Trade ₹57.99 Cr ₹57.89 Cr ₹51.89 Cr ₹50.29 Cr ₹56.54 Cr ₹40.23 Cr ₹42.62 Cr ₹44.61 Cr ₹40.26 Cr ₹37.64 Cr ₹44.8 Cr ₹39.46 Cr
Changes in Inventories -₹49.56 Cr -₹38.23 Cr ₹24.39 Cr ₹6.08 Cr -₹15.1 Cr ₹4 Cr ₹17.6 Cr -₹25.08 Cr -₹59.42 Cr ₹31.01 Cr -₹28.16 Cr ₹34.4 Cr
Employee Benefit Expense ₹313.49 Cr ₹306.16 Cr ₹293.44 Cr ₹280.96 Cr ₹257.86 Cr ₹245.71 Cr ₹241.65 Cr ₹265.68 Cr ₹215.97 Cr ₹216.41 Cr ₹205.48 Cr ₹196.3 Cr
Finance Costs -₹74 Lakh ₹1.87 Cr ₹73 Lakh ₹73 Lakh ₹67 Lakh ₹2.48 Cr ₹73 Lakh ₹72 Lakh ₹1.42 Cr ₹2.36 Cr ₹2.27 Cr ₹75 Lakh
Depreciation & Amortisation ₹44.16 Cr ₹42.38 Cr ₹41.92 Cr ₹40.31 Cr ₹38.76 Cr ₹34.93 Cr ₹33.32 Cr ₹32.92 Cr ₹33.47 Cr ₹33.41 Cr ₹33.04 Cr ₹32.24 Cr
Other Expenses ₹393.79 Cr ₹304.75 Cr ₹343.33 Cr ₹334.75 Cr ₹274.03 Cr ₹265.51 Cr ₹317.04 Cr ₹237.82 Cr ₹243.08 Cr ₹234.01 Cr ₹225.86 Cr ₹249.71 Cr
Total Expenses ₹1,015.9 Cr ₹909.89 Cr ₹973.3 Cr ₹920.2 Cr ₹803.72 Cr ₹803 Cr ₹860.05 Cr ₹795.08 Cr ₹733.81 Cr ₹793.88 Cr ₹706.84 Cr ₹770.67 Cr
Profit Before Exceptional Items & Tax ₹257.61 Cr ₹322.46 Cr ₹321.97 Cr ₹328.99 Cr ₹228.15 Cr ₹332.15 Cr ₹309.2 Cr ₹310.56 Cr ₹225.94 Cr ₹305.14 Cr ₹290.5 Cr ₹275.37 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹257.61 Cr ₹322.46 Cr ₹321.97 Cr ₹328.99 Cr ₹228.15 Cr ₹332.15 Cr ₹309.2 Cr ₹310.56 Cr ₹225.94 Cr ₹305.14 Cr ₹290.5 Cr ₹275.37 Cr
Total Tax Expense ₹60.33 Cr ₹77.42 Cr ₹72.44 Cr ₹74.02 Cr ₹34.72 Cr ₹79.7 Cr ₹74.22 Cr ₹74.53 Cr ₹63.25 Cr ₹84.99 Cr ₹78.14 Cr ₹63.33 Cr
Net Profit ₹197.28 Cr ₹245.04 Cr ₹249.53 Cr ₹254.97 Cr ₹193.43 Cr ₹252.45 Cr ₹234.98 Cr ₹236.03 Cr ₹162.69 Cr ₹220.15 Cr ₹212.36 Cr ₹212.04 Cr
Other Comprehensive Income ₹2.28 Cr ₹19 Lakh ₹47 Lakh -₹3.25 Cr -₹1.43 Cr -₹41 Lakh -₹1.56 Cr -₹2.43 Cr -₹93 Lakh -₹56 Lakh -₹41 Lakh -₹62 Lakh
Total Comprehensive Income ₹199.56 Cr ₹245.23 Cr ₹250 Cr ₹251.72 Cr ₹192 Cr ₹252.04 Cr ₹233.42 Cr ₹233.6 Cr ₹161.76 Cr ₹219.59 Cr ₹211.95 Cr ₹211.42 Cr
EBITDA (computed) ₹301.03 Cr ₹366.71 Cr ₹364.62 Cr ₹370.03 Cr ₹267.58 Cr ₹369.56 Cr ₹343.25 Cr ₹344.2 Cr ₹260.83 Cr ₹340.91 Cr ₹325.81 Cr ₹308.36 Cr
Basic EPS ₹15.79 ₹19.61 ₹19.98 ₹20.41 ₹15.46 ₹20.16 ₹18.75 ₹18.77 ₹12.92 ₹17.48 ₹16.87 ₹16.84
Diluted EPS ₹15.79 ₹19.61 ₹19.97 ₹20.40 ₹15.45 ₹20.15 ₹18.74 ₹18.75 ₹12.91 ₹17.47 ₹16.85 ₹16.84
Latest 12 quarters shown of 24 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Ajanta Pharma Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Ajanta Pharma Limited

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 66.25%, foreign institutional investors hold 8.26%, domestic institutional investors hold 18.37%, retail and other public shareholders hold 7.12% of Ajanta Pharma Limited. The company had 67,955 shareholders on record.

Promoters: 66.25%DII (Domestic Institutional): 18.37%FII (Foreign Institutional): 8.26%Retail & Others: 7.12%
Mar 2026
QUARTER
66.25% Promoters
18.37% DII (Domestic Institutional)
8.26% FII (Foreign Institutional)
7.12% Retail & Others
Promoter holding - history
Now 66.25% · Mar 2026High 73.78% · Dec 2015Low 66.11% · Dec 2022
65%67.5%70%72.5%75%Dec 2015Mar 2018Dec 2020Jun 2023Mar 2026Dec 2015: 73.78%Mar 2016: 73.78%Jun 2016: 73.78%Sep 2016: 73.78%Nov 2016: 73.78%Dec 2016: 73.78%Mar 2017: 73.78%Jun 2017: 73.78%Jul 2017: 70.71%Sep 2017: 70.70%Dec 2017: 70.70%Mar 2018: 70.70%Jun 2018: 70.48%Sep 2018: 70.47%Dec 2018: 70.47%Mar 2019: 70.52%Jun 2019: 70.52%Sep 2019: 70.51%Dec 2019: 70.51%Mar 2020: 70.51%Jun 2020: 70.51%Sep 2020: 70.51%Dec 2020: 70.34%Mar 2021: 70.34%Jun 2021: 70.34%Sep 2021: 70.34%Dec 2021: 70.34%Mar 2022: 70.48%Jun 2022: 70.48%Sep 2022: 70.48%Dec 2022: 66.11%Mar 2023: 66.11%Apr 2023: 66.21%Jun 2023: 66.21%Sep 2023: 66.21%Dec 2023: 66.21%Mar 2024: 66.21%Jun 2024: 66.27%Sep 2024: 66.26%Dec 2024: 66.26%Mar 2025: 66.26%Jun 2025: 66.26%Sep 2025: 66.25%Dec 2025: 66.25%Mar 2026: 66.25%73.78%66.11%66.25%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters66.25%66.25%66.25%66.26%66.26%66.26%
Public33.75%33.75%33.75%33.74%33.74%33.74%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Promoters66.25%66.26%66.21%66.11%70.48%70.34%70.51%70.52%70.70%73.78%73.78%
Public33.75%33.74%33.79%33.89%29.52%29.66%29.49%29.48%29.30%26.22%26.22%
Promoter change (YoY, %pts)-0.01+0.05+0.10-4.37+0.14-0.17-0.01-0.18-3.08+0.00-

Board & Governance of Ajanta Pharma Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Ajanta Pharma Limited has 8 directors - 4 independent and 3 executive. The board is chaired by Mannalal B. Agrawal.

DirectorPositionOn board sinceListed boards
Mannalal B. Agrawal Non-Executive - Non Independent Director · Chairperson 1979-12-31 1
Madhusudan B. Agrawal Executive Director 1979-12-31 1
Yogesh Mannalal Agrawal Executive Director · MD 2000-04-29 1
Rajesh Mannalal Agrawal Executive Director 2013-04-30 1
David Rasquinha Non-Executive - Independent Director 2024-05-02 2
Medha Vinay Joshi Non-Executive - Independent Director 2024-05-02 1
Rajesh Shashikant Dalal Non-Executive - Independent Director 2024-05-02 3
Simi Manohar Lal Thapar Non-Executive - Independent Director 2024-05-02 1
Board Committees
CommitteeMembers
Audit Committee David Rasquinha (Chairperson), Mannalal B. Agrawal, Rajesh Shashikant Dalal, Simi Manohar Lal Thapar
Nomination and remuneration committee Rajesh Shashikant Dalal (Chairperson), David Rasquinha, Medha Vinay Joshi
Stakeholders Relationship Committee Mannalal B. Agrawal (Chairperson), Rajesh Mannalal Agrawal, Simi Manohar Lal Thapar
Risk Management Committee Yogesh Mannalal Agrawal (Chairperson), Rajesh Mannalal Agrawal, Rajesh Shashikant Dalal, Arvind Agrawal
Corporate Social Responsibility Committee Mannalal B. Agrawal (Chairperson), Madhusudan B. Agrawal, Yogesh Mannalal Agrawal, Medha Vinay Joshi

Charges & Borrowings of Ajanta Pharma Limited

Open charges
₹65 Cr
Satisfied charges
₹548.84 Cr
Breakdown by lending institutions
Citi Bank N.A.₹35.00 Cr
Others₹20.00 Cr
Idbi Bank Limited₹10.00 Cr
Latest charge details
DateLenderAmountStatus
25 Jan 2024 Idbi Bank Limited ₹10 Cr Open
11 Feb 2021 Others ₹10 Cr Open
26 Jun 2020 Citi Bank N.A. ₹35 Cr Open
03 Jul 1997 Others ₹10 Cr Open
21 Mar 2013 State Bank of Mauritius Limited ₹55.16 Cr Satisfied

Total charge records: 35 View all charges

Employees and EPFO Compliance at Ajanta Pharma Limited

Ajanta Pharma Limited has a workforce of 7,869 employees as of Sep 23, 2025.

Employee count
7,869
Active EPFO establishments
9
Employee growth
2.85%
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Employee Count & EPFO Data of Ajanta Pharma Limited

Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.

Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification

GST Compliance of Ajanta Pharma Limited

XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS

GSTIN & GST Filing Data of Ajanta Pharma Limited

Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.

GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution

Credit Ratings, Litigation & Regulatory Alerts for Ajanta Pharma Limited

Credit rating
AAA
AA+
AA
AA-
! !
2015 2017 2019 2021 2023
Litigation
District Court 35
High Court 45
Supreme Court 0
NCLT / NCLAT 0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults

Credit Ratings, Legal Cases & Regulatory Alerts of Ajanta Pharma Limited

Access complete credit rating history, litigation records, regulatory alerts, and compliance data.

Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)

MSME Payment Delays by Ajanta Pharma Limited

MSME Payment Delays by Ajanta Pharma Limited

Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.

Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal

Subsidiaries & Group Companies of Ajanta Pharma Limited

Subsidiaries & Group Companies of Ajanta Pharma Limited

See the full corporate group - holding company, subsidiaries, associates and joint ventures of Ajanta Pharma Limited with ownership details.

Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year

MCA Filings & Documents of Ajanta Pharma Limited

MCA Filings & Documents of Ajanta Pharma Limited

Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.

Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates

Recent Activity on Ajanta Pharma Limited

Activity
17 Jul 2025
Ajanta Pharma Limited last Annual general meeting of members was held on 17 Jul 2025 as per latest MCA records.
Activity
31 Mar 2025
Ajanta Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai.
Directors
02 May 2024
David Paul Rasquinha was appointed as a Director on 02 May 2024 & has been associated with this company since 2 years 2 months.
Directors
02 May 2024
Simi Manohar Lal Thapar was appointed as a Director on 02 May 2024 & has been associated with this company since 2 years 2 months.
Directors
02 May 2024
Rajesh Shashikant Dalal was appointed as a Director on 02 May 2024 & has been associated with this company since 2 years 2 months.
Directors
02 May 2024
Medha Vinay Joshi was appointed as a Director on 02 May 2024 & has been associated with this company since 2 years 2 months.

Recent News on Ajanta Pharma Limited

Stocks that will see action today January 30, 2025
30 Jan 2025 · Thehindubusinessline

Frequently Asked Questions about Ajanta Pharma Limited

Ajanta Pharma Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 31 December 1979 (47+ years old) and is registered under CIN L24230MH1979PLC022059. Listed on BSE: 532331 and NSE: AJANTPHARM. The company has 7,869 employees.

Ajanta Pharma Limited reported revenue of ₹4,742.6 Cr for FY 2025 (up 10.00% YoY).

The current directors of Ajanta Pharma Limited are:

The primary industry of Ajanta Pharma Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Ajanta Pharma Limited is listed on both BSE (code: 532331) and NSE (symbol: AJANTPHARM).

Ajanta Pharma Limited can be reached at the registered office: Ajanta Tower 54 – A M Vasanji Road, Chakala Andheri E, Mumbai, Maharashtra, India – 400093, or through the website ajantapharma.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available